Towards precision medicine for AML
With rapid advances in sequencing technologies, tremendous progress has been made in
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …
Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management
Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …
cancer characterized by unbridled proliferation of malignant marrow stem cells with …
[HTML][HTML] T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments
N Daver, AS Alotaibi, V Bücklein, M Subklewe - Leukemia, 2021 - nature.com
Acute myeloid leukemia (AML) is a heterogeneous disease linked to a broad spectrum of
molecular alterations, and as such, long-term disease control requires multiple therapeutic …
molecular alterations, and as such, long-term disease control requires multiple therapeutic …
[HTML][HTML] Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
Z Tian, M Liu, Y Zhang, X Wang - Journal of hematology & oncology, 2021 - Springer
Harnessing the power of immune cells, especially T cells, to enhance anti-tumor activities
has become a promising strategy in clinical management of hematologic malignancies. The …
has become a promising strategy in clinical management of hematologic malignancies. The …
TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
NG Daver, A Maiti, TM Kadia, P Vyas, R Majeti, AH Wei… - Cancer discovery, 2022 - AACR
TP53-mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) form a
distinct group of myeloid disorders with dismal outcomes. TP53-mutated MDS and AML …
distinct group of myeloid disorders with dismal outcomes. TP53-mutated MDS and AML …
[HTML][HTML] Emerging agents and regimens for AML
H Liu - Journal of hematology & oncology, 2021 - Springer
Until recently, acute myeloid leukemia (AML) patients used to have limited treatment options,
depending solely on cytarabine+ anthracycline (7+ 3) intensive chemotherapy and …
depending solely on cytarabine+ anthracycline (7+ 3) intensive chemotherapy and …
Acute myeloid leukaemia
CD DiNardo, HP Erba, SD Freeman, AH Wei - The Lancet, 2023 - thelancet.com
Progress in acute myeloid leukaemia treatment is occurring at an unprecedented pace. The
past decade has witnessed an increasingly improved scientific understanding of the …
past decade has witnessed an increasingly improved scientific understanding of the …
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for
diagnosis and management of acute myeloid leukemia (AML) in adults are widely …
diagnosis and management of acute myeloid leukemia (AML) in adults are widely …
[HTML][HTML] Recent advances in targeted therapies in acute myeloid leukemia
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival
for younger patients over the last several decades has improved nearly sixfold with the …
for younger patients over the last several decades has improved nearly sixfold with the …
[HTML][HTML] Catch me if you can: how AML and its niche escape immunotherapy
S Tettamanti, A Pievani, A Biondi, G Dotti, M Serafini - Leukemia, 2022 - nature.com
In spite of the remarkable progress in basic and preclinical studies of acute myeloid
leukemia (AML), the five-year survival rate of AML patients remains poor, highlighting the …
leukemia (AML), the five-year survival rate of AML patients remains poor, highlighting the …